Non-Invasive Artificial Intelligence-Based Platform MonIToring Program (NIP IT!)
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorUniversity Health Network, Toronto
About this trial
Patients who have undergone curative treatment may be at risk of relapse. This study will collect, annotate, and sequence biospecimens (blood, stool, and tissue) from patients across different tumor types to detect molecular residual disease (MRD) before metastases become radiographically or clinically detectable. This will allow for early cancer interception, and hopefully prolong relapse-free survival across tumor types.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Patients with histological confirmation of a solid tumor.
Patients must have early stage or locally advanced disease that is planned for or have undergone curative treatment.
Patient must be ≥ 18 years old.
All patients must have signed and dated an informed consent form.
Disqualifiers
None
Trial population
Early stage or locally advanced disease that is planned for or have undergone curative treatment.
Trial design
Design model
Cohort
Time perspective
Prospective
Treatments tested in this trial
Not listed
Trial groups
800 Participants
are grouped into 1 trial groupGroup A: NIP IT!
Trial outcomes
Primary outcomes
1
Change from Baseline in ctDNA collected from biospecimens
Next-generation sequencing based ctDNA analysis
Time frame
Through study completion, an average of 4 yearsSecondary outcomes
1
Number of participants that are identified as high risk of clinical relapse with artificial intelligence (AI) and machine learning algorithms
Time frame
Through study completion, an average of 4 yearsSponsors and contacts
Click on the lead sponsor to view all of their trials.
University Health Network, Toronto
Lead sponsor
Princess Margaret Hospital, Canada
Collaborator
Source ClinicalTrials.gov